{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=93", "query": { "condition": "Relapsed, Refractory Malignant Neoplasms", "page": 93 }, "page_size": 10 }, "pagination": { "page": 93, "page_size": 10, "total_count": 3448, "total_pages": 345, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=94&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=92&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T11:38:21.065Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00044018", "title": "CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CDC-501", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2002-04-01", "completion_date": "2007-02-15", "has_results": false, "last_update_posted_date": "2019-11-12", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 4, "location_summary": "Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044018" }, { "nct_id": "NCT01118013", "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "donor lymphocytes", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "reduced-intensity transplant conditioning procedure", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "69 Years", "sex": "ALL", "summary": "Up to 69 Years" }, "enrollment_count": 6, "start_date": "2010-12", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2017-03-24", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 10, "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more", "locations": [ { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Elkton MD", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01118013" }, { "nct_id": "NCT05217082", "title": "A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [], "intervention_types": [], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 35, "start_date": "2022-02-22", "completion_date": "2022-08-03", "has_results": false, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 1, "location_summary": "Morrisville, North Carolina", "locations": [ { "city": "Morrisville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05217082" }, { "nct_id": "NCT03850574", "title": "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute", "Refractory AML", "Relapsed Adult AML", "Myelodysplastic Syndrome With Excess Blasts-2", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Tuspetinib", "type": "DRUG" }, { "name": "Venetoclax Oral Tablet", "type": "DRUG" }, { "name": "Azacitidine for Intravenous Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aptose Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2019-03-11", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • Irvine, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03850574" }, { "nct_id": "NCT06871410", "title": "Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Autologous Anti-CD83 CAR T-cells", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2026-02-02", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06871410" }, { "nct_id": "NCT02397720", "title": "Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2015-04-07", "completion_date": "2023-10-09", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02397720" }, { "nct_id": "NCT00764517", "title": "Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Indolent Adult Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2008-08", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2017-12-11", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 2, "location_summary": "Portland, Oregon • Hershey, Pennsylvania", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00764517" }, { "nct_id": "NCT05139017", "title": "A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "DLBCL", "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Zilovertamab vedotin", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Granulocyte Colony-Stimulating Factor (G-CSF)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2022-01-14", "completion_date": "2027-09-24", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 26, "location_summary": "Glendale, Arizona • Beverly Hills, California • Walnut Creek, California + 23 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05139017" }, { "nct_id": "NCT05652335", "title": "A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma", "Previously Treated Amyloid Light-chain (AL) Amyloidosis" ], "interventions": [ { "name": "JNJ-79635322", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2022-11-22", "completion_date": "2030-11-15", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 9, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05652335" }, { "nct_id": "NCT01282476", "title": "Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Panobinostat with Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-06", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-27T11:38:21.065Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01282476" } ] }